KEYNOTE-057 update: pembrolizumab for high-risk NMIBC patients VJOncology 3:16 5 years ago 256 Далее Скачать
Copy of Dr. Balar on Next Steps of the KEYNOTE-057 Trial in NMIBC OncLive 0:45 5 years ago 14 Далее Скачать
KEYNOTE-057: extended follow-up of pembrolizumab in bladder cancer VJOncology 2:22 3 years ago 309 Далее Скачать
Dr. Balar Discusses Study of Immunotherapy Combination in Bladder Cancer OncLive 1:32 6 years ago 195 Далее Скачать
Updates from KEYNOTE 57: Pembrolizumab for patients with bladder cancer ecancer 3:02 5 years ago 197 Далее Скачать
Dr. Balar on Biomarkers of Immunotherapy Response in Bladder Cancer OncLive 0:54 5 years ago 85 Далее Скачать
Keynote 057 - Pre test, post test and further readings conference workshop 13:50 4 years ago 116 Далее Скачать
Dr. Balar on Improved Outlook in Metastatic Bladder Cancer OncLive 1:09 5 years ago 137 Далее Скачать
Yair Lotan, MD, shares outcomes of KEYNOTE 057 in high-risk non-muscle-invasive bladder cancer OBRoncology 1:49 5 years ago 161 Далее Скачать
Dr. Balar on the Approval of Pembrolizumab for Bladder Cancer OncLive 0:51 7 years ago 96 Далее Скачать
Management of BCG Unresponsive Cystectomy Ineligible Bladder Cancer Patients Pembrolizumab Grand Rounds in Urology 10:35 3 years ago 1 312 Далее Скачать
Dr. Balar on Current and Future Standards of Care in Kidney Cancer Treatment OncLive 1:09 6 years ago 158 Далее Скачать
Dr. Balar on Remaining Questions With Immunotherapy in Bladder Cancer OncLive 1:57 6 years ago 65 Далее Скачать
Copy of Dr. Balar Discusses the Impact of Immunotherapy on Bladder Cancer OncLive 0:06 6 years ago 20 Далее Скачать
